Methodology and Evidence Review An extensive evidence review, which included literature derived from research involving human subjects, published in English, and indexed in MEDLINE (through PubMed), EMBASE, the Cochrane Library, the Agency for Healthcare Research and Quality, and other selected databases relevant to this guide- line, was conducted between February and August 2015. Key search words included but were not limited to the following: adherence; aerobic; alcohol intake; ambulatory care; antihy- pertensive: agents, drug, medication, therapy; beta adrener- gic blockers; blood pressure: arterial, control, determination, devices, goal, high, improve, measurement, monitoring, ambu- latory; calcium channel blockers; diet; diuretic agent; drug therapy; heart failure: diastolic, systolic; hypertension: white coat, masked, ambulatory, isolated ambulatory, isolated clinic, diagnosis, reverse white coat, prevention, therapy, treatment, control; intervention; lifestyle: measures, modification; office visits; patient outcome; performance measures; physical activity; potassium intake; protein intake; renin inhibitor; risk reduction: behavior, counseling; screening; sphygmomanom- eters; spironolactone; therapy; treatment: adherence, compli- ance, efficacy, outcome, protocol, regimen; weight. Additional relevant studies published through June 2016, during the guide- line writing process, were also considered by the writing com- mittee and added to the evidence tables when appropriate. The final evidence tables included in the Online Data Supplement summarize the evidence used by the writing committee to for- mulate recommendations. As noted in the preamble, an independent ERC was com- missioned to perform a formal systematic review of 4 criti- cal clinical questions related to hypertension (Table 2), the results of which were considered by the writing committee for incorporation into this guideline. Concurrent with this pro- cess, writing committee members evaluated other published data relevant to the guideline. 